Turning Medical Insights into Patient Impact - Summary - MDSpire

Turning Medical Insights into Patient Impact

  • By

  • Manuel Möller

  • May 21, 2026

Share

Objective:

To address the underutilization of medical insights in biopharma and propose a specific framework for operationalizing these insights to improve patient outcomes.

Key Findings:
  • Up to 90% of medicines in clinical development do not reach the market due to various barriers.
  • KOLs believe only 30% of their insights are utilized by biopharma organizations, indicating a significant gap.
  • Insight capture is inconsistent and fragmented, leading to lost intelligence on patient needs and unmet medical requirements.
  • AI can transform insight analysis, enabling real-time detection of medical themes and improving decision-making.
Interpretation:

Closing the insights gap is crucial for biopharma to enhance patient care and ensure that therapies are aligned with real-world needs, ultimately leading to better patient outcomes.

Limitations:
  • The article does not provide specific case studies or examples of successful implementation, limiting practical applicability.
  • Potential challenges in standardizing processes across diverse organizations are not addressed, which could hinder implementation.
Conclusion:

A commitment to a structured approach in utilizing medical insights can elevate the role of medical affairs and improve patient outcomes, as evidenced by potential case studies.

Original Source(s)

Turning Medical Insights into Patient Impact

  • by Manuel Möller

  • May 21, 2026

Related Content

Rethinking Progress in Clinical Trials

Three clinical development leaders discuss how early signals, trial design, regulatory expectations, and patient access are reshaping clinical development

  • May 20, 2026

  • 11 min
Roswell Park Experts Report on Discovery of Rare Bladder Cells, Neural Mapping of Pelvic Floor Muscles at AUA 2026

Evidence provided by a Roswell Park study indicates that neoadjuvant chemotherapy may be the preferred course of treatment for patients with non-muscle-invasive bladder cancer (NMIBC) when their disease progresses and they are diagnosed with muscle-invasive bladder cancer (MIBC)

  • by

  • May 19, 2026

  • 7 min
This Week’s Biopharma News: FDA Commissioner Steps Down

Marty Makary’s resignation puts the agency under acting leadership, while BMS and Hengrui unveil a multibillion-dollar pipeline deal and GSK lines up a chronic hepatitis B launch in China.

  • May 19, 2026

  • 4 min